エピジェネティクス市場 : 2028年までの世界予測

Report Overview

The global epigenetics market size is projected to reach USD 4.3 billion by 2028 from USD 1.8 billion in 2023, at a CAGR of 18.3% during the forecast period. Factors such as increased investments in research and development, coupled with a reduction in sequencing costs and time, support from government initiatives and funding for epigenetics research, advancements in technology for epigenetic research, and a growing interest in epigenetic-based therapeutics.

“The kits & reagents segment segment held the dominant share in the epigenetics market”
Based on product & service, the global epigenetics market is segmented into kits & reagents, enzymes, instruments and accessories, software, and service. The kits & reagents segment  is anticipated to grow at significant CAGR. The rapid expansion of epigenetics studies, combined with the introduction of cost-effective and user-friendly kits by market participants are likely to have positive impact on the growth of the market.

“DNA methylation segment accounted for the largest share of the method segment in 2022.”
Based on method, the epigenetics market is segmented into, DNA methylation, histone modifications, and other methods. In 2022, the DNA methylation segment accounted for the largest share of the epigenetics market. The segment held the dominant share in the market owing to the effectiveness of employing DNA methylation techniques for cancer research.

“Asia Pacific region is likely to grow at a faster pace in the epigenetics market.”
The epigenetics market region is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and the Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by enhancements in healthcare infrastructure within developing APAC economies, coupled with strategic partnerships, collaborations, agreements, and expansions pursued by local industry players.
 
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 60%, and Demand Side – 40%
• By Designation (Supply Side): Managers – 45%, CXOs & Directors – 30%, Executives- 25%
• By Region: North America: 40%, Europe: 27%, Asia Pacific: 20%, Latin America: 10%, and the Middle East & Africa: 3%

List of Companies Profiled in the Report:
• Thermo Fisher Scientific Inc. (US)
• Merck KGaA (Germany)
• Illumina, Inc. (US)
• PacBio (US)
• Abcam plc (UK)
• Active Motif, Inc. (US)
• Bio-Rad Laboratories Inc. (US)
• Promega Corporation (US)
• Revvity (US)
• Qiagen (Germany)
• New England Biolabs (US)
• Zymo Research Corporation (US)
• Diagenode SA(US)
• F. Hoffmann-La Roche Ltd (Switzerland)
• EpiGentek Group Inc. (US)
• EpiCypher (US)
• Fios Genomics (UK)
• GenomeScan (Netherlands)
• Creative Biogene (US)
• BPS Bioscienc Inc (US)
• Abnova Corporation (Taiwan)
• Creative Diagnostics (US)
• Biomodal (UK)
• Integrated DNA Technologies Inc. (US)
• Novogene Co Ltd (China)

Research Coverage:
This report provides a detailed picture of the epigenetics market. It aims at estimating the size and future growth potential of the market across different segments such as the technology, type, disease indication, route of administration, end-user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall epigenetics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:
• Analysis of key drivers (growing investment in research & development, declining sequencing cost & time, favorable government initiatives and funding for epigenetics research, technological advancements in epigenetic research and rising demand for epigenetic-based therapeutics), restraints (Limited application of epigenomic data in toxicology, data privacy concern and security issues associated with management of large scale- epigenetic data ), opportunities (Expanding application of epigenetics and integration of artificial intelligence and machine learning algorithm) and challenges (Concerns Regarding the Quality of Antibodies, Challenges associated epigenetics editing, off target effect) are influencing the growth of epigenetics market.
• Product Development/Innovation: Detailed insights on newly launched products of the epigenetics market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the epigenetics market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the epigenetics market. 
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Active Motif, Inc. (US), Bio-Rad Laboratories Inc. (US), Promega Corporation (US), Revvity (US) and Qiagen (Germany).

Table of Contents

1            INTRODUCTION            44

1.1         STUDY OBJECTIVES      44

1.2         MARKET DEFINITION   44

1.2.1      INCLUSIONS & EXCLUSIONS     45

1.3         MARKET SCOPE             45

1.3.1      MARKETS COVERED     45

1.3.2      YEARS CONSIDERED     46

1.3.3      CURRENCY CONSIDERED          46

1.4         RESEARCH LIMITATIONS           46

1.5         STAKEHOLDERS            47

1.6         SUMMARY OF CHANGES            47

1.7         RECESSION IMPACT      48

2            RESEARCH METHODOLOGY     49

2.1         RESEARCH DATA           49

FIGURE 1           RESEARCH DESIGN       49

2.1.1      SECONDARY DATA       50

2.1.2      PRIMARY DATA 51

FIGURE 2           BREAKDOWN OF PRIMARIES     51

2.2         MARKET SIZE ESTIMATION       52

FIGURE 3           MARKET SIZE ESTIMATION: EPIGENETICS MARKET (2022)              52

FIGURE 4           APPROACH 1: REVENUE SHARE ANALYSIS          53

FIGURE 5           REVENUE SHARE ANALYSIS OF THERMO FISHER SCIENTIFIC INC.: EPIGENETICS MARKET (2022)        53

2.2.1      PRIMARY INSIGHTS       54

FIGURE 6           MARKET VALIDATION FROM PRIMARY EXPERTS           54

2.2.2      SEGMENTAL ASSESSMENT: EPIGENETICS MARKET        55

FIGURE 7           MARKET SIZE ESTIMATION: TOP-DOWN APPROACH    55

2.3         GROWTH RATE ASSUMPTIONS 56

FIGURE 8           CAGR PROJECTION: EPIGENETICS MARKET      56

FIGURE 9           GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES,  AND OPPORTUNITIES  57

2.4         MARKET BREAKDOWN & DATA TRIANGULATION          58

FIGURE 10         DATA TRIANGULATION METHODOLOGY         58

2.5         STUDY ASSUMPTIONS  59

2.6         RISK ANALYSIS 59

2.7         RECESSION IMPACT: EPIGENETICS MARKET     59

TABLE 1             GLOBAL INFLATION RATE PROJECTION, 2021–2028 (% GROWTH)         60

TABLE 2             US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)  60

TABLE 3             US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)  60

3            EXECUTIVE SUMMARY 61

FIGURE 11         EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 61

FIGURE 12         EPIGENETICS MARKET, BY METHOD, 2023 VS. 2028 (USD MILLION)          62

FIGURE 13         EPIGENETICS MARKET, BY TECHNIQUE, 2023 VS. 2028 (USD MILLION)          62

FIGURE 14         EPIGENETICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)          63

FIGURE 15         EPIGENETICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)          63

FIGURE 16         GEOGRAPHICAL SNAPSHOT OF EPIGENETICS MARKET 64

4            PREMIUM INSIGHTS      65

4.1         EPIGENETICS MARKET OVERVIEW        65

FIGURE 17         DECLINING SEQUENCING COSTS & TIME TO DRIVE MARKET GROWTH DURING FORECAST PERIOD 65

4.2         NORTH AMERICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2022)  66

FIGURE 18         KITS & REAGENTS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN EPIGENETICS MARKET IN 2022   66

4.3         EPIGENETICS MARKET SHARE, BY PRODUCT & SERVICE,  2023 VS. 2028              67

FIGURE 19         KITS & REAGENTS SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2028             67

4.4         EPIGENETICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES              67

FIGURE 20         ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATES FROM 2023 TO 2028         67

5            MARKET OVERVIEW     68

5.1         INTRODUCTION            68

5.2         MARKET DYNAMICS     68

FIGURE 21         EPIGENETICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    68

TABLE 4             IMPACT ANALYSIS: EPIGENETICS MARKET        69

5.2.1      DRIVERS            69

5.2.1.1   Growing investments in research & development         69

5.2.1.2   Declining sequencing costs & time   70

FIGURE 22         COST OF HUMAN WHOLE-GENOME SEQUENCING, 2001–2020              71

5.2.1.3   Favorable government initiatives and funding for epigenetics research     72

5.2.1.4   Technological advancements in epigenetics research   72

5.2.1.5   Rising demand for epigenetic-based therapeutics         73

FIGURE 23         NUMBER OF CANCER CASES IN US, 2017–2022    74

5.2.2      RESTRAINTS     74

5.2.2.1   Limited applications of epigenomic data in toxicology 74

5.2.2.2   Data privacy concerns and security issues      75

5.2.3      OPPORTUNITIES           75

5.2.3.1   Expanding applications of epigenetics            75

5.2.3.2   Integration of artificial intelligence and machine learning algorithms       76

5.2.4      CHALLENGES   76

5.2.4.1   Concerns regarding quality of antibodies       76

5.2.4.2   Challenges associated with epigenetic editing 77

5.3         TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77

FIGURE 24         REVENUE SHIFT AND NEW REVENUE POCKETS FOR EPIGENETICS PROVIDERS         77

5.4         PRICING ANALYSIS        78

5.4.1      AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYER         78

TABLE 5             AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYER              78

5.4.2      AVERAGE SELLING PRICE TREND          79

5.5         TECHNOLOGY ANALYSIS           79

5.6         VALUE CHAIN ANALYSIS            80

FIGURE 25         VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE     80

5.7         ECOSYSTEM MAP          81

FIGURE 26         ECOSYSTEM MAP          81

TABLE 6             ROLE IN ECOSYSTEM: EPIGENETICS MARKET   81

5.8         REGULATORY ANALYSIS            83

TABLE 7             KEY REGULATORY AGENCIES   83

5.8.1      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS          85

TABLE 8             NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         85

TABLE 9             EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86

TABLE 10           ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         86

TABLE 11           LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         87

TABLE 12           MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         87

TABLE 13           AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88

5.9         PORTER’S FIVE FORCES ANALYSIS         88

TABLE 14           PORTER’S FIVE FORCES ANALYSIS: EPIGENETICS MARKET              88

5.9.1      THREAT OF NEW ENTRANTS    88

5.9.2      THREAT OF SUBSTITUTES         89

5.9.3      BARGAINING POWER OF SUPPLIERS     89

5.9.4      BARGAINING POWER OF BUYERS           89

5.9.5      INTENSITY OF COMPETITIVE RIVALRY 89

5.10       PATENT ANALYSIS        90

FIGURE 27         PATENT APPLICATIONS FOR EPIGENETICS, NOVEMBER 2013–NOVEMBER 2023            90

TABLE 15           INDICATIVE LIST OF PATENTS: EPIGENETICS MARKET 90

5.11       KEY CONFERENCES & EVENTS  91

TABLE 16           DETAILED LIST OF KEY CONFERENCES & EVENTS, 2023–2024              91

5.12       KEY STAKEHOLDERS & BUYING CRITERIA          92

5.12.1    KEY STAKEHOLDERS IN BUYING PROCESS         92

FIGURE 28         INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF EPIGENETICS   92

5.12.2    BUYING CRITERIA FOR EPIGENETICS   93

FIGURE 29         KEY BUYING CRITERIA FOR END USERS              93

6            EPIGENETICS MARKET, BY PRODUCT & SERVICE           94

6.1         INTRODUCTION            95

TABLE 17           EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 95

6.2         KITS & REAGENTS         95

TABLE 18           EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION)     96

TABLE 19           EPIGENETICS MARKET FOR KITS & REAGENTS, BY REGION, 2021–2028 (USD MILLION)          96

TABLE 20           NORTH AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY,  2021–2028 (USD MILLION)  97

TABLE 21           EUROPE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY,  2021–2028 (USD MILLION) 97

TABLE 22           ASIA PACIFIC: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY,  2021–2028 (USD MILLION)         98

TABLE 23           LATIN AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY,  2021–2028 (USD MILLION)  98

6.2.1      ANTIBODIES     98

6.2.1.1   Growing demand for recombinant antibodies for detection of epigenetic targets to propel growth      98

TABLE 24           EPIGENETICS MARKET FOR ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)     99

TABLE 25           NORTH AMERICA: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY,  2021–2028 (USD MILLION)         100

TABLE 26           EUROPE: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY,  2021–2028 (USD MILLION) 100

TABLE 27           ASIA PACIFIC: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY,  2021–2028 (USD MILLION) 101

TABLE 28           LATIN AMERICA: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY,  2021–2028 (USD MILLION) 101

6.2.2      CHIP-SEQUENCING KITS & REAGENTS 101

6.2.2.1   Versatile applications of chromatin immunoprecipitation (ChIP) pertaining to epigenetic regulatory systems to boost demand            101

TABLE 29           EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY REGION,  2021–2028 (USD MILLION)      102

TABLE 30           NORTH AMERICA: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS,  BY COUNTRY, 2021–2028 (USD MILLION)              102

TABLE 31           EUROPE: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 103

TABLE 32           ASIA PACIFIC: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS,  BY COUNTRY, 2021–2028 (USD MILLION)   103

TABLE 33           LATIN AMERICA: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS,  BY COUNTRY, 2021–2028 (USD MILLION)              104

6.2.3      BISULFITE CONVERSION KITS & REAGENTS      104

6.2.3.1   Effective outcomes associated with bisulfite conversion to drive demand  104

TABLE 34           EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY REGION, 2021–2028 (USD MILLION)        105

TABLE 35           NORTH AMERICA: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION)              105

TABLE 36           EUROPE: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS,  BY COUNTRY, 2021–2028 (USD MILLION)   106

TABLE 37           ASIA PACIFIC: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS,  BY COUNTRY, 2021–2028 (USD MILLION)              106

TABLE 38           LATIN AMERICA: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION)              107

6.2.4      WHOLE-GENOME AMPLIFICATION KITS & REAGENTS  107

6.2.4.1   Ability of whole-genome amplification to maintain relative proportions of genes in original pool to drive adoption     107

TABLE 39           EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS,  BY REGION, 2021–2028 (USD MILLION)              108

TABLE 40           NORTH AMERICA: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION)          108

TABLE 41           EUROPE: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION)              109

TABLE 42           ASIA PACIFIC: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION)              109

TABLE 43           LATIN AMERICA: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION)          110

6.2.5      5-HMC & 5-MC ANALYSIS KITS & REAGENTS      110

6.2.5.1   Introduction of unique kits for 5-mC and 5-hmC analysis to support growth              110

TABLE 44           EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY REGION, 2021–2028 (USD MILLION)        111

TABLE 45           NORTH AMERICA: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 111

TABLE 46           EUROPE: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS,  BY COUNTRY, 2021–2028 (USD MILLION)   112

TABLE 47           ASIA PACIFIC: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 112

TABLE 48           LATIN AMERICA: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 113

6.2.6      HISTONES         113

6.2.6.1   Emerging importance of chromatin-associated proteins and histones in epigenetic research to drive segmental growth  113

TABLE 49           EPIGENETICS MARKET FOR HISTONES, BY REGION, 2021–2028 (USD MILLION) 114

TABLE 50           NORTH AMERICA: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY,  2021–2028 (USD MILLION) 114

TABLE 51          EUROPE: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY,  2021–2028 (USD MILLION)          115

TABLE 52           ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY,  2021–2028 (USD MILLION) 115

TABLE 53           LATIN AMERICA: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY,  2021–2028 (USD MILLION) 116

6.2.7      OTHER KITS & REAGENTS         116

TABLE 54           EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY REGION,  2021–2028 (USD MILLION)     117

TABLE 55           NORTH AMERICA: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION)     117

TABLE 56           EUROPE: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY,  2021–2028 (USD MILLION)  118

TABLE 57           ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY,  2021–2028 (USD MILLION)  118

TABLE 58           LATIN AMERICA: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION)     119

6.3         ENZYMES          119

TABLE 59           EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 119

TABLE 60           EPIGENETICS MARKET FOR ENZYMES, BY REGION, 2021–2028 (USD MILLION) 120

TABLE 61           NORTH AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY,  2021–2028 (USD MILLION) 120

TABLE 62           EUROPE: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)          120

TABLE 63           ASIA PACIFIC: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY,  2021–2028 (USD MILLION) 121

TABLE 64           LATIN AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY,  2021–2028 (USD MILLION) 121

6.3.1      DNA-MODIFYING ENZYMES      121

6.3.1.1   Broadening applications of DNA methylation to favor market growth      121

TABLE 65           EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY REGION,  2021–2028 (USD MILLION)     122

TABLE 66           NORTH AMERICA: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)            122

TABLE 67           EUROPE: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY COUNTRY,  2021–2028 (USD MILLION)    123

TABLE 68           ASIA PACIFIC: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)       123

TABLE 69           LATIN AMERICA: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)            124

6.3.2      PROTEIN-MODIFYING ENZYMES            124

6.3.2.1   Increasing pipeline of epigenetics-based drugs targeting histone-modifying enzymes to drive segmental growth  124

TABLE 70           EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY REGION,  2021–2028 (USD MILLION)             125

TABLE 71           NORTH AMERICA: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES,  BY COUNTRY, 2021–2028 (USD MILLION)          125

TABLE 72           EUROPE: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)       126

TABLE 73           ASIA PACIFIC: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)            126

TABLE 74           LATIN AMERICA: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES,  BY COUNTRY, 2021–2028 (USD MILLION)          127

6.3.3      OTHER ENZYMES          127

TABLE 75           EPIGENETICS MARKET FOR OTHER ENZYMES, BY REGION, 2021–2028 (USD MILLION)          127

TABLE 76           NORTH AMERICA: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY,  2021–2028 (USD MILLION)    128

TABLE 77           EUROPE: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY,  2021–2028 (USD MILLION) 128

TABLE 78           ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY,  2021–2028 (USD MILLION)         129

TABLE 79           LATIN AMERICA: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY,  2021–2028 (USD MILLION)    129

6.4         INSTRUMENTS & ACCESSORIES 129

6.4.1      WIDE USAGE OF NGS INSTRUMENTS AND SONICATORS TO PROPEL GROWTH          129

TABLE 80           EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY REGION,  2021–2028 (USD MILLION)             130

TABLE 81           NORTH AMERICA: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES,  BY COUNTRY, 2021–2028 (USD MILLION)       130

TABLE 82           EUROPE: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2021–2028 (USD MILLION) 131

TABLE 83           ASIA PACIFIC: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2021–2028 (USD MILLION) 131

TABLE 84           LATIN AMERICA: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES,  BY COUNTRY, 2021–2028 (USD MILLION)           132

6.5         SOFTWARE       132

6.5.1      DEVELOPMENT OF VIABLE SOFTWARE SOLUTIONS FOR DNA METHYLATION AND RNA ANALYSIS TO PROPEL GROWTH        132

TABLE 85           EPIGENETICS MARKET FOR SOFTWARE, BY REGION, 2021–2028 (USD MILLION) 133

TABLE 86           NORTH AMERICA: EPIGENETICS MARKET FOR SOFTWARE, BY COUNTRY,  2021–2028 (USD MILLION) 133

TABLE 87           EUROPE: EPIGENETICS MARKET FOR SOFTWARE, BY COUNTRY,  2021–2028 (USD MILLION) 134

TABLE 88           ASIA PACIFIC: EPIGENETICS MARKET FOR SOFTWARE, BY COUNTRY,  2021–2028 (USD MILLION) 134

TABLE 89           LATIN AMERICA: EPIGENETICS MARKET FOR SOFTWARE, BY COUNTRY,  2021–2028 (USD MILLION) 135

6.6         SERVICES          135

6.6.1      EXPANDING POOL OF SERVICE PROVIDERS TO DRIVE GROWTH              135

TABLE 90           EPIGENETICS MARKET FOR SERVICES, BY REGION, 2021–2028 (USD MILLION) 136

TABLE 91           NORTH AMERICA: EPIGENETICS MARKET FOR SERVICES, BY COUNTRY,  2021–2028 (USD MILLION) 136

TABLE 92           EUROPE: EPIGENETICS MARKET FOR SERVICES, BY COUNTRY,  2021–2028 (USD MILLION)          137

TABLE 93           ASIA PACIFIC: EPIGENETICS MARKET FOR SERVICES, BY COUNTRY,  2021–2028 (USD MILLION) 137

TABLE 94           LATIN AMERICA: EPIGENETICS MARKET FOR SERVICES, BY COUNTRY,  2021–2028 (USD MILLION) 138

7            EPIGENETICS MARKET, BY METHOD    139

7.1         INTRODUCTION            140

TABLE 95           EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION)          140

7.2         DNA METHYLATION     140

7.2.1      INCREASING R&D ACTIVITIES TO EXPLORE POTENTIAL OF DNA METHYLATION TO DRIVE MARKET GROWTH   140

TABLE 96           EPIGENETICS MARKET FOR DNA METHYLATION, BY REGION, 2021–2028 (USD MILLION)          141

TABLE 97           NORTH AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY,  2021–2028 (USD MILLION)        141

TABLE 98           EUROPE: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY,  2021–2028 (USD MILLION) 142

TABLE 99           ASIA PACIFIC: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY,  2021–2028 (USD MILLION)        142

TABLE 100         LATIN AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY,  2021–2028 (USD MILLION)        143

7.3         HISTONE MODIFICATIONS        143

7.3.1      TECHNOLOGICAL ADVANCEMENTS TO DRIVE SEGMENTAL GROWTH              143

TABLE 101         COMMON HISTONE MODIFICATIONS AND RESPECTIVE LOCATIONS      144

TABLE 102         EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY REGION,  2021–2028 (USD MILLION)     144

TABLE 103         NORTH AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)        145

TABLE 104         EUROPE: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY,  2021–2028 (USD MILLION)     145

TABLE 105         ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)        146

TABLE 106         LATIN AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)        146

7.4         OTHER METHODS         146

TABLE 107         EPIGENETICS MARKET FOR OTHER METHODS, BY REGION, 2021–2028 (USD MILLION)          147

TABLE 108         NORTH AMERICA: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY,  2021–2028 (USD MILLION)   147

TABLE 109         EUROPE: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY,  2021–2028 (USD MILLION) 148

TABLE 110         ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY,  2021–2028 (USD MILLION)         148

TABLE 111         LATIN AMERICA: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY,  2021–2028 (USD MILLION)   149

8            EPIGENETICS MARKET, BY TECHNIQUE             150

8.1         INTRODUCTION            151

TABLE 112         EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)          151

8.2         NGS      151

8.2.1      ABILITY TO OFFER COMPREHENSIVE EPIGENETIC PROFILES TO PROPEL DEMAND FOR NGS TECHNIQUE           151

TABLE 113         EPIGENETICS MARKET FOR NGS, BY REGION, 2021–2028 (USD MILLION)          152

TABLE 114         NORTH AMERICA: EPIGENETICS MARKET FOR NGS, BY COUNTRY,  2021–2028 (USD MILLION) 152

TABLE 115         EUROPE: EPIGENETICS MARKET FOR NGS, BY COUNTRY, 2021–2028 (USD MILLION)     153

TABLE 116         ASIA PACIFIC: EPIGENETICS MARKET FOR NGS, BY COUNTRY, 2021–2028 (USD MILLION)          153

TABLE 117         LATIN AMERICA: EPIGENETICS MARKET FOR NGS, BY COUNTRY,  2021–2028 (USD MILLION) 154

8.3         PCR & QPCR      154

8.3.1      RISING NUMBER OF PCR-BASED EPIGENETICS SERVICE PROVIDERS TO DRIVE GROWTH      154

TABLE 118         EPIGENETICS MARKET FOR PCR & QPCR, BY REGION, 2021–2028 (USD MILLION)     155

TABLE 119         NORTH AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY,  2021–2028 (USD MILLION) 155

TABLE 120         EUROPE: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY,  2021–2028 (USD MILLION) 156

TABLE 121         ASIA PACIFIC: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY,  2021–2028 (USD MILLION) 156

TABLE 122         LATIN AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY,  2021–2028 (USD MILLION) 157

8.4         MASS SPECTROMETRY 157

8.4.1      GROWING DEMAND FOR MASS SPECTROMETRY IN COMPREHENSIVE STUDIES ON HISTONE EPIGENETICS TO BOOST MARKET          157

TABLE 123         EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION,  2021–2028 (USD MILLION)     158

TABLE 124         NORTH AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2021–2028 (USD MILLION)        158

TABLE 125         EUROPE: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY,  2021–2028 (USD MILLION)         159

TABLE 126         ASIA PACIFIC: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY,  2021–2028 (USD MILLION)      159

TABLE 127         LATIN AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY,  2021–2028 (USD MILLION)      160

8.5         SONICATION    160

8.5.1      INTRODUCTION OF IMPROVED HIGH-THROUGHPUT SONICATION TECHNIQUES TO PROPEL ADOPTION  160

TABLE 128         EPIGENETICS MARKET FOR SONICATION, BY REGION, 2021–2028 (USD MILLION)     161

TABLE 129         NORTH AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY,  2021–2028 (USD MILLION)         161

TABLE 130         EUROPE: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY,  2021–2028 (USD MILLION) 162

TABLE 131         ASIA PACIFIC: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY,  2021–2028 (USD MILLION) 162

TABLE 132         LATIN AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY,  2021–2028 (USD MILLION) 163

8.6         OTHER TECHNIQUES   163

TABLE 133         EPIGENETICS MARKET FOR OTHER TECHNIQUES, BY REGION, 2021–2028 (USD MILLION)          164

TABLE 134         NORTH AMERICA: EPIGENETICS MARKET FOR OTHER TECHNIQUES, BY COUNTRY,  2021–2028 (USD MILLION)           164

TABLE 135         EUROPE: EPIGENETICS MARKET FOR OTHER TECHNIQUES, BY COUNTRY,  2021–2028 (USD MILLION) 165

TABLE 136         ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER TECHNIQUES, BY COUNTRY,  2021–2028 (USD MILLION)           165

TABLE 137         LATIN AMERICA: EPIGENETICS MARKET FOR OTHER TECHNIQUES, BY COUNTRY,  2021–2028 (USD MILLION)           166

9            EPIGENETICS MARKET, BY APPLICATION          167

9.1         INTRODUCTION            168

TABLE 138         EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          168

9.2         ONCOLOGY      168

9.2.1      GROWING EFFORTS TO DEVELOP ONCOLOGY EPIGENETIC DRUGS TO BOOST MARKET      168

TABLE 139         EPIGENOME-TARGETING CANCER DRUGS APPROVED OR IN CLINICAL TRIALS          169

TABLE 140         EPIGENETICS MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)     171

TABLE 141         NORTH AMERICA: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY,  2021–2028 (USD MILLION) 171

TABLE 142         EUROPE: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY,  2021–2028 (USD MILLION) 172

TABLE 143         ASIA PACIFIC: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY,  2021–2028 (USD MILLION) 172

TABLE 144         LATIN AMERICA: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY,  2021–2028 (USD MILLION) 173

9.3         METABOLIC DISEASES 173

9.3.1      EMERGING ROLE OF DNA METHYLATION IN DIABETES MANAGEMENT TO FAVOR MARKET GROWTH  173

TABLE 145         EPIGENETICS MARKET FOR METABOLIC DISEASES, BY REGION,  2021–2028 (USD MILLION)     174

TABLE 146         NORTH AMERICA: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)       174

TABLE 147         EUROPE: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)         175

TABLE 148         ASIA PACIFIC: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)     175

TABLE 149         LATIN AMERICA: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)     176

9.4         IMMUNOLOGY 176

9.4.1      GROWING DEMAND FOR EPIGENETIC PRODUCTS IN TUMOR AND TRANSPLANTATION IMMUNOLOGY TO SUPPORT GROWTH    176

TABLE 150         EPIGENETICS MARKET FOR IMMUNOLOGY, BY REGION, 2021–2028 (USD MILLION)     177

TABLE 151         NORTH AMERICA: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)         177

TABLE 152         EUROPE: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY,  2021–2028 (USD MILLION) 178

TABLE 153         ASIA PACIFIC: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY,  2021–2028 (USD MILLION) 178

TABLE 154         LATIN AMERICA: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)         179

9.5         DEVELOPMENTAL BIOLOGY    179

9.5.1      INCREASING RESEARCH IN DEVELOPMENTAL BIOLOGY TO PROPEL GROWTH          179

TABLE 155         EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION,  2021–2028 (USD MILLION)     180

TABLE 156         NORTH AMERICA: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 180

TABLE 157         EUROPE: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)     181

TABLE 158         ASIA PACIFIC: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)       181

TABLE 159         LATIN AMERICA: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 182

9.6         CARDIOVASCULAR DISEASES   182

9.6.1      EMERGING ROLE OF EPIGENETICS IN UNDERSTANDING ETIOLOGY OF CARDIOVASCULAR DISEASES TO BOOST ADOPTION            182

TABLE 160         EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION,  2021–2028 (USD MILLION)     183

TABLE 161         NORTH AMERICA: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)              183

TABLE 162         EUROPE: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)     184

TABLE 163         ASIA PACIFIC: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)       184

TABLE 164         LATIN AMERICA: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 185

9.7         OTHER APPLICATIONS 185

TABLE 165         EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION,  2021–2028 (USD MILLION)     186

TABLE 166         NORTH AMERICA: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY,  2021–2028 (USD MILLION)        186

TABLE 167         EUROPE: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY,  2021–2028 (USD MILLION)         187

TABLE 168         ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY,  2021–2028 (USD MILLION)        187

TABLE 169         LATIN AMERICA: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY,  2021–2028 (USD MILLION)        188

10          EPIGENETICS MARKET, BY END USER   189

10.1       INTRODUCTION            190

TABLE 170         EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION)          190

10.2       ACADEMIC & RESEARCH INSTITUTES   190

10.2.1    INCREASING GOVERNMENT INVESTMENTS & COLLABORATIONS TO CONTRIBUTE TO MARKET GROWTH    190

TABLE 171         EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION,  2021–2028 (USD MILLION)   191

TABLE 172         NORTH AMERICA: EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,  BY COUNTRY, 2021–2028 (USD MILLION)        191

TABLE 173         EUROPE: EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)  192

TABLE 174         ASIA PACIFIC: EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,  BY COUNTRY, 2021–2028 (USD MILLION)        192

TABLE 175         LATIN AMERICA: EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,  BY COUNTRY, 2021–2028 (USD MILLION)        193

10.3       PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES   193

10.3.1    GROWING NUMBER OF CLINICAL TRIALS FOR EPIGENETICS-BASED DRUGS TO DRIVE GROWTH      193

TABLE 176         EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES,  BY REGION, 2021–2028 (USD MILLION)              194

TABLE 177         NORTH AMERICA: EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 194

TABLE 178         EUROPE: EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)              195

TABLE 179         ASIA PACIFIC: EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)              195

TABLE 180         LATIN AMERICA: EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 196

10.4       HOSPITALS & CLINICS  196

10.4.1    GROWING IMPORTANCE OF MEASUREMENT OF DNA METHYLATION IN HOSPITAL SETTINGS TO BOOST MARKET    196

TABLE 181        EPIGENETICS MARKET FOR HOSPITALS & CLINICS, BY REGION,  2021–2028 (USD MILLION)          197

TABLE 182         NORTH AMERICA: EPIGENETICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)         197

TABLE 183         EUROPE: EPIGENETICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY,  2021–2028 (USD MILLION)         198

TABLE 184         ASIA PACIFIC: EPIGENETICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY,  2021–2028 (USD MILLION)       198

TABLE 185         LATIN AMERICA: EPIGENETICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY,  2021–2028 (USD MILLION)       199

11          EPIGENETICS MARKET, BY REGION       200

11.1       INTRODUCTION            201

TABLE 186         EPIGENETICS MARKET, BY REGION, 2021–2028 (USD MILLION)              201

11.2       NORTH AMERICA          201

FIGURE 30         NORTH AMERICA: EPIGENETICS MARKET SNAPSHOT   202

TABLE 187         NORTH AMERICA: EPIGENETICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)     202

TABLE 188         NORTH AMERICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)    203

TABLE 189         NORTH AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,  2021–2028 (USD MILLION)           203

TABLE 190         NORTH AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,  2021–2028 (USD MILLION)          204

TABLE 191         NORTH AMERICA: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION)     204

TABLE 192         NORTH AMERICA: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)          204

TABLE 193         NORTH AMERICA: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          205

TABLE 194         NORTH AMERICA: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION)     205

11.2.1    US         205

11.2.1.1 Strong network of well-established epigenetic product manufacturers to drive market growth     205

TABLE 195         US: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 206

TABLE 196         US: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION)          207

TABLE 197         US: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 207

TABLE 198         US: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION)          208

TABLE 199         US: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)          208

TABLE 200         US: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          209

TABLE 201         US: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION)          209

11.2.2    CANADA            209

11.2.2.1 Increasing government initiatives to boost epigenetics research 209

TABLE 202         CANADA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)          210

TABLE 203         CANADA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,  2021–2028 (USD MILLION)          211

TABLE 204         CANADA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION)          211

TABLE 205         CANADA: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION)          212

TABLE 206         CANADA: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 212

TABLE 207         CANADA: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 213

TABLE 208         CANADA: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 213

11.3       NORTH AMERICA: RECESSION IMPACT 213

11.4       EUROPE             214

TABLE 209         EUROPE: EPIGENETICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 214

TABLE 210         EUROPE: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)          215

TABLE 211         EUROPE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,  2021–2028 (USD MILLION)          215

TABLE 212         EUROPE: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION)          216

TABLE 213         EUROPE: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION)          216

TABLE 214         EUROPE: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 216

TABLE 215         EUROPE: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 217

TABLE 216         EUROPE: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 217

11.4.1    GERMANY         217

11.4.1.1 Significant investments in NGS to boost adoption of epigenetics products              217

TABLE 217         GERMANY: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)          218

TABLE 218         GERMANY: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,  2021–2028 (USD MILLION)          219

TABLE 219         GERMANY: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION)          219

TABLE 220         GERMANY: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 220

TABLE 221         GERMANY: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 220

TABLE 222         GERMANY: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)     220

TABLE 223         GERMANY: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 221

11.4.2    UK         221

11.4.2.1 Rising acceptance of genome-based diagnostic techniques by clinicians to support growth   221

TABLE 224         UK: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)     222

TABLE 225         UK: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION)          222

TABLE 226         UK: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 223

TABLE 227         UK: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION)          223

TABLE 228         UK: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)          223

TABLE 229         UK: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          224

TABLE 230         UK: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION)          224

11.4.3    FRANCE             224

11.4.3.1 Growing demand for PCR technologies to propel market growth             224

TABLE 231         FRANCE: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)          225

TABLE 232         FRANCE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,  2021–2028 (USD MILLION)          225

TABLE 233         FRANCE: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION)     226

TABLE 234         FRANCE: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION)          226

TABLE 235         FRANCE: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 226

TABLE 236         FRANCE: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 227

TABLE 237         FRANCE: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION)          227

11.4.4    ITALY   227

11.4.4.1 High incidence of cancer to support market growth     227

TABLE 238         ITALY: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)     228

TABLE 239        ITALY: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,  2021–2028 (USD MILLION)          228

TABLE 240         ITALY: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION)     229

TABLE 241         ITALY: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION)          229

TABLE 242         ITALY: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 229

TABLE 243         ITALY: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 230

TABLE 244         ITALY: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION)          230

11.4.5    SPAIN   230

11.4.5.1 Well-established network of research centers and universities to boost market              230

TABLE 245         SPAIN: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)     231

TABLE 246        SPAIN: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,  2021–2028 (USD MILLION)          231

TABLE 247         SPAIN: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION)     232

TABLE 248         SPAIN: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION)          232

TABLE 249         SPAIN: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 232

TABLE 250         SPAIN: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 233

TABLE 251         SPAIN: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION)          233

11.4.6    REST OF EUROPE           233

TABLE 252         REST OF EUROPE: EPIGENETICS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)    234

TABLE 253         REST OF EUROPE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,  2021–2028 (USD MILLION)           234

TABLE 254         REST OF EUROPE: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,  2021–2028 (USD MILLION)          235

TABLE 255         REST OF EUROPE: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION)     235

TABLE 256         REST OF EUROPE: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)          235

TABLE 257         REST OF EUROPE: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          236

TABLE 258         REST OF EUROPE: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION)     236

11.5       EUROPE: RECESSION IMPACT   236

11.6       ASIA PACIFIC    237

FIGURE 31         ASIA PACIFIC: EPIGENETICS MARKET SNAPSHOT          238

TABLE 259         ASIA PACIFIC: EPIGENETICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 239

TABLE 260        ASIA PACIFIC: EPIGENETICS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)          239

TABLE 261         ASIA PACIFIC: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,  2021–2028 (USD MILLION)    240

TABLE 262         ASIA PACIFIC: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,  2021–2028 (USD MILLION)          240

TABLE 263         ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 241

TABLE 264         ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)     241

TABLE 265         ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)     242

TABLE 266         ASIA PACIFIC: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 242

11.6.1    JAPAN  242

11.6.1.1 Increasing collaborations between research & academic organizations to favor market growth     242

TABLE 267         JAPAN: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)     243

TABLE 268         JAPAN: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,  2021–2028 (USD MILLION)          244

TABLE 269         JAPAN: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION)     244

TABLE 270         JAPAN: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION)          245

TABLE 271         JAPAN: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 245

TABLE 272         JAPAN: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 246

TABLE 273         JAPAN: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION)          246

11.6.2    CHINA  246

11.6.2.1 High demand for personalized medicine to fuel growth 246

TABLE 274         CHINA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)     247

TABLE 275         CHINA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,  2021–2028 (USD MILLION)          248

TABLE 276         CHINA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION)     248

TABLE 277         CHINA: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION)          249

TABLE 278         CHINA: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 249

TABLE 279         CHINA: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 250

TABLE 280         CHINA: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION)          250

11.6.3    INDIA   250

11.6.3.1 Expanding base of biotechnology facilities to drive growth         250

TABLE 281         INDIA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)     251

TABLE 282        INDIA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,  2021–2028 (USD MILLION)          252

TABLE 283         INDIA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION)     252

TABLE 284         INDIA: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION)          253

TABLE 285         INDIA: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 253

TABLE 286         INDIA: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 254

TABLE 287         INDIA: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION)          254

11.6.4    SOUTH KOREA 254

11.6.4.1 Increasing demand for epigenetic testing to boost growth          254

TABLE 288         SOUTH KOREA: EPIGENETICS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)    255

TABLE 289         SOUTH KOREA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,  2021–2028 (USD MILLION)    255

TABLE 290         SOUTH KOREA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,  2021–2028 (USD MILLION)          256

TABLE 291         SOUTH KOREA: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION)     256

TABLE 292         SOUTH KOREA: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)     256

TABLE 293         SOUTH KOREA: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          257

TABLE 294         SOUTH KOREA: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION)     257

11.6.5    REST OF ASIA PACIFIC  257

TABLE 295         REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)    258

TABLE 296         REST OF ASIA PACIFIC: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,  2021–2028 (USD MILLION)           258

TABLE 297         REST OF ASIA PACIFIC: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,  2021–2028 (USD MILLION)    259

TABLE 298         REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION)          259

TABLE 299        REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNIQUE,  2021–2028 (USD MILLION)          259

TABLE 300         REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION,  2021–2028 (USD MILLION)        260

TABLE 301         REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION)          260

11.6.6    ASIA PACIFIC: RECESSION IMPACT        260

11.7       LATIN AMERICA             261

TABLE 302         LATIN AMERICA: EPIGENETICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)     261

TABLE 303         LATIN AMERICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)    262

TABLE 304         LATIN AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,  2021–2028 (USD MILLION)           262

TABLE 305         LATIN AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,  2021–2028 (USD MILLION)          263

TABLE 306         LATIN AMERICA: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION)     263

TABLE 307         LATIN AMERICA: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)          263

TABLE 308         LATIN AMERICA: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          264

TABLE 309         LATIN AMERICA: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION)     264

11.7.1    BRAZIL 264

11.7.1.1 Increasing number of healthcare providers incorporating epigenetic testing to boost growth        264

TABLE 310         BRAZIL: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)          265

TABLE 311         BRAZIL: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,  2021–2028 (USD MILLION)          265

TABLE 312         BRAZIL: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION)     266

TABLE 313         BRAZIL: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION)          266

TABLE 314         BRAZIL: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 266

TABLE 315         BRAZIL: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 267

TABLE 316         BRAZIL: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION)          267

11.7.2    MEXICO             267

11.7.2.1 Growing adoption of cutting-edge technologies to support growth           267

TABLE 317         MEXICO: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)          268

TABLE 318         MEXICO: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,  2021–2028 (USD MILLION)          268

TABLE 319         MEXICO: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION)     269

TABLE 320         MEXICO: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION)          269

TABLE 321         MEXICO: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 269

TABLE 322         MEXICO: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 270

TABLE 323         MEXICO: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION)          270

11.7.3    REST OF LATIN AMERICA          270

TABLE 324         REST OF LATIN AMERICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)         271

TABLE 325         REST OF LATIN AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS,  BY TYPE, 2021–2028 (USD MILLION)           271

TABLE 326         REST OF LATIN AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,  2021–2028 (USD MILLION)             272

TABLE 327        REST OF LATIN AMERICA: EPIGENETICS MARKET, BY METHOD,  2021–2028 (USD MILLION)          272

TABLE 328         REST OF LATIN AMERICA: EPIGENETICS MARKET, BY TECHNIQUE,  2021–2028 (USD MILLION)           272

TABLE 329         REST OF LATIN AMERICA: EPIGENETICS MARKET, BY APPLICATION,  2021–2028 (USD MILLION)        273

TABLE 330         REST OF LATIN AMERICA: EPIGENETICS MARKET, BY END USER,  2021–2028 (USD MILLION)          273

11.7.4    LATIN AMERICA: RECESSION IMPACT   273

11.8       MIDDLE EAST  274

11.8.1    INCREASE IN FUNDING AND PARTNERSHIPS IN RESEARCH SECTOR TO BOOST GROWTH           274

TABLE 331         MIDDLE EAST: EPIGENETICS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)    274

TABLE 332         MIDDLE EAST: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,  2021–2028 (USD MILLION)    275

TABLE 333         MIDDLE EAST: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,  2021–2028 (USD MILLION)          275

TABLE 334         MIDDLE EAST: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 276

TABLE 335         MIDDLE EAST: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)     276

TABLE 336         MIDDLE EAST: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)     277

TABLE 337         MIDDLE EAST: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION)     277

11.8.2    MIDDLE EAST: RECESSION IMPACT       277

11.9       AFRICA 278

11.9.1    GROWING COLLABORATIONS TO SUPPORT GROWTH IN COMING YEARS  278

TABLE 338         AFRICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)          278

TABLE 339         AFRICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,  2021–2028 (USD MILLION)          279

TABLE 340         AFRICA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION)     279

TABLE 341         AFRICA: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION)          280

TABLE 342         AFRICA: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 280

TABLE 343         AFRICA: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 281

TABLE 344         AFRICA: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION)          281

11.9.2    AFRICA: RECESSION IMPACT     281

12          COMPETITIVE LANDSCAPE       282

12.1       INTRODUCTION            282

12.2       STRATEGIES ADOPTED BY KEY PLAYERS           283

FIGURE 32         EPIGENETICS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS           283

12.3       REVENUE ANALYSIS      284

FIGURE 33         REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022            284

12.4       MARKET SHARE ANALYSIS         284

FIGURE 34         EPIGENETICS MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022) 285

TABLE 345         EPIGENETICS MARKET: DEGREE OF COMPETITION      285

12.5       COMPANY EVALUATION MATRIX          286

12.5.1    STARS  286

12.5.2    EMERGING LEADERS    287

12.5.3    PERVASIVE PLAYERS     287

12.5.4    PARTICIPANTS 287

FIGURE 35         EPIGENETICS MARKET: COMPANY EVALUATION MATRIX, 2022              288

12.5.5    COMPANY FOOTPRINT ANALYSIS         289

TABLE 346         EPIGENETICS MARKET: PRODUCT FOOTPRINT ANALYSIS              289

TABLE 347         EPIGENETICS MARKET: REGIONAL FOOTPRINT ANALYSIS              290

12.6       START-UP/SME EVALUATION QUADRANT        291

12.6.1    PROGRESSIVE COMPANIES       291

12.6.2    RESPONSIVE COMPANIES          291

12.6.3    DYNAMIC COMPANIES 291

12.6.4    STARTING BLOCKS       291

FIGURE 36        EPIGENETICS MARKET: START-UP/SME EVALUATION MATRIX, 2022      292

12.6.5    COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS   293

TABLE 348         EPIGENETICS MARKET: DETAILS OF START-UP/SME PLAYERS              293

TABLE 349         EPIGENETICS MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SME PLAYERS         294

12.7       COMPETITIVE SCENARIO & TRENDS     294

12.7.1    PRODUCT LAUNCHES & APPROVALS    294

TABLE 350         EPIGENETICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–SEPTEMBER 2023            294

12.7.2    DEALS  295

TABLE 351         EPIGENETICS MARKET: DEALS, JANUARY 2021–SEPTEMBER 2023      295

12.7.3    OTHER DEVELOPMENTS           296

TABLE 352         EPIGENETICS MARKET: OTHER DEVELOPMENTS, JANUARY 2021–SEPTEMBER 2023  296

13          COMPANY PROFILES    297

(Business overview, Products offered, Recent Developments, MNM view)*

13.1       KEY MARKET PLAYERS 297

13.1.1    THERMO FISHER SCIENTIFIC INC.          297

TABLE 353         THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW              297

FIGURE 37         THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)   298

13.1.2    ILLUMINA, INC. 301

TABLE 354         ILLUMINA, INC.: BUSINESS OVERVIEW  301

FIGURE 38         ILLUMINA, INC.: COMPANY SNAPSHOT (2022)  302

13.1.3    MERCK KGAA   305

TABLE 355         MERCK KGAA: BUSINESS OVERVIEW     305

FIGURE 39         MERCK KGAA: COMPANY SNAPSHOT (2022)      306

13.1.4    PACBIO 309

TABLE 356         PACBIO: BUSINESS OVERVIEW  309

FIGURE 40         PACBIO: COMPANY SNAPSHOT (2022)  310

13.1.5    ABCAM PLC      313

TABLE 357         ABCAM PLC: BUSINESS OVERVIEW        313

FIGURE 41         ABCAM PLC: COMPANY SNAPSHOT (2022)         314

13.1.6    BIO-RAD LABORATORIES, INC. 317

TABLE 358         BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW   317

FIGURE 42         BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)              318

13.1.7    ACTIVE MOTIF INC.       322

TABLE 359         ACTIVE MOTIF INC.: BUSINESS OVERVIEW        322

13.1.8    NEW ENGLAND BIOLABS           326

TABLE 360         NEW ENGLAND BIOLABS: BUSINESS OVERVIEW             326

13.1.9    QIAGEN             329

TABLE 361         QIAGEN: BUSINESS OVERVIEW 329

FIGURE 43         QIAGEN: COMPANY SNAPSHOT (2022)  330

13.1.10  ZYMO RESEARCH CORPORATION          332

TABLE 362         ZYMO RESEARCH CORPORATION: BUSINESS OVERVIEW              332

13.1.11  REVVITY            335

TABLE 363         REVVITY: BUSINESS OVERVIEW 335

FIGURE 44         REVVITY: COMPANY SNAPSHOT (2022) 336

13.1.12  DIAGENODE SA (A HOLOGIC COMPANY)           338

TABLE 364         DIAGENODE SA (A HOLOGIC COMPANY): BUSINESS OVERVIEW        338

13.1.13  F. HOFFMANN-LA ROCHE LTD. 341

TABLE 365         F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW  341

FIGURE 45         F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)              342

13.1.14  PROMEGA CORPORATION        343

TABLE 366         PROMEGA CORPORATION: BUSINESS OVERVIEW          343

13.1.15  EPIGENTEK GROUP INC.            345

TABLE 367         EPIGENTEK GROUP INC.: BUSINESS OVERVIEW 345

13.2       OTHER PLAYERS           349

13.2.1    EPICYPHER       349

13.2.2    FIOS GENOMICS            350

13.2.3    GENOMESCAN 351

13.2.4    CREATIVE BIOGENE     352

13.2.5    BPS BIOSCIENCE, INC.   353

13.2.6    ABNOVA CORPORATION           354

13.2.7    CREATIVE DIAGNOSTICS           355

13.2.8    BIOMODAL (FORMERLY CAMBRIDGE EPIGENETIX)      356

13.2.9    INTEGRATED DNA TECHNOLOGIES, INC.          356

13.2.10  NOVOGENE CO., LTD.  358

*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

14          APPENDIX         359

14.1       DISCUSSION GUIDE      359

14.2       KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL             363

14.3       CUSTOMIZATION OPTIONS      365

14.4       RELATED REPORTS       365

14.5       AUTHOR DETAILS         366